Fungal infection in tarantulas, clinically termed mycosis, represents a serious condition where pathogenic fungi colonize and invade the spider's exoskeleton or internal tissues, causing progressive damage and often death if untreated. These infections can range from superficial colonization of the outer cuticle to deep systemic invasion affecting the respiratory book lungs, digestive organs, and other vital tissues. Unlike bacterial infections that may progress rapidly, fungal infections often develop insidiously over extended periods, with visible symptoms appearing only after significant tissue colonization has already occurred.
Mycosis can affect any tarantula species maintained in captivity, though certain conditions dramatically increase susceptibility. Species requiring high humidity face elevated risk because the same moist conditions they need for health also favor fungal proliferation. Specimens maintained in enclosures with poor ventilation that allows stagnant, saturated air accumulation experience particularly high infection rates. Tropical species from rainforest environments require careful balance between necessary humidity and ventilation that prevents fungal overgrowth. Arboreal species in particular seem susceptible, possibly because their elevated position within enclosures sometimes receives less air circulation than substrate level.
The impact of fungal infection on tarantula health depends on infection location and depth. Surface infections may remain relatively benign if the spider can outgrow them through molting, shedding the infected cuticle with the old exoskeleton. However, deeper infections penetrating the book lungs compromise respiratory function, while systemic infections spreading through internal tissues cause organ damage and eventual death. The insidious nature of fungal growth means that significant internal damage may occur before external symptoms become obvious, making early detection challenging and prognosis uncertain even when infection is identified.
Treatability of fungal infections in tarantulas remains extremely limited compared to fungal disease treatment in other animals. No antifungal medications are approved for arachnid use, and dosing protocols for off-label treatments remain poorly established and potentially dangerous. The primary treatment approach focuses on environmental correction to create conditions unfavorable for fungal growth while remaining suitable for the tarantula. Reducing humidity, increasing ventilation, and sometimes completely replacing contaminated substrate may halt fungal progression. Early intervention offers the best prognosis, as advanced infections with deep tissue involvement are generally not treatable, making prevention through appropriate husbandry far more effective than any available treatment.
